HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Gravity Works As WeWork Doesn't; Now Plan B

Bifurcated Chinese Express Market Developing

Thematic (Sector/Industry)

Hong kong Healthcare equipment and services / Thematic (Sector/Industry)

1. Industry viewpoints:<ul>
<li>With the aggravation of aging, the number of stroke patients would grow rapidly and it is estimated that the potential market size of neurointerventional medical devices would reach RMB33.3 billion in 2025</li>
<li>China has a huge demographic dividend and demand for vision correction. It is expected to be a large growth space for orthokeratology lenses industry in China.</li>
<li>Pet medical industry started late in China, but it develops rapidly.</li>
</ul>2. Company news:News about the progress of new drugs of <a href="https://www.smartkarma.com/entities/everest-medicines" target="_blank" data-smartkarma-citation="entities:29224:1" rel="noopener">Everest Medicines (1952 HK)</a>, <a href="https://www.smartkarma.com/entities/antengene-corporation-limited" target="_blank" data-smartkarma-citation="entities:29705:1" rel="noopener">Antengene (6996 HK)</a> and <a href="https://www.smartkarma.com/entities/jacobio-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:29696:1" rel="noopener">Jacobio Pharmaceuticals (1167 HK)</a>.3. Market review:Last week, stock price for healthcare sector in A share increased 2.88%, while CSI 300 increased 5.45% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1. Industry viewpoints:
With the aggravation of aging, the number of stroke patients would grow rapidly and it is estimated that the potential market size of neurointerventional medical devices would reach RMB33.3 billion in 2025
China has a huge demographic dividend and demand for vision correction. It is expected to be a large growth space for orthokeratology lenses industry in China.
Pet medical industry started late in China, but it develops rapidly.
2. Company news:News about the progress of new drugs of Everest Medicines (1952 HK), Antengene (6996 HK) and Jacobio Pharmaceuticals (1167 HK).3. Market review:Last week, stock price for healthcare sector in A share increased 2.88%, while CSI 300 increased 5.45% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

China Healthcare Weekly (Jan.8)